M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Erlotinib Prevention of Oral Cancer (EPOC)

Phase 3

Completed

Conditions: Oral Cancer

Interventions: Drug: Placebo
Drug: Erlotinib

First Posted Date: 2006-11-22

Last Posted Date: 2020-04-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 303

Registration Number: NCT00402779

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
The Univeristy of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Malignant Pleural Effusion With ZD6474

Phase 2

Terminated

Conditions: Lung Cancer
Pleural Effusion

Interventions: Drug: ZD6474

First Posted Date: 2006-11-22

Last Posted Date: 2016-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00402896

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Thymoglobulin
Drug: Busulfan
Drug: Fludarabine
Procedure: Alloreactive NK Infusion
Drug: G-CSF
Drug: Tacrolimus
Drug: Methotrexate
Drug: Interleukin-2

First Posted Date: 2006-11-22

Last Posted Date: 2015-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00402558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2006-11-14

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00398983

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Chemoradiation-Induced Nausea and Emesis: Quality of Life

Terminated

Conditions: Gastric Cancer
Anal Cancer
Pancreatic Cancer
Vulvar Cancer
Cervical Cancer
Endometrial Cancer

Interventions: Behavioral: Interview
Other: Questionnaire

First Posted Date: 2006-11-01

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 207

Registration Number: NCT00394602

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Targeted Intervention for Melanoma Prevention

Not Applicable

Completed

Conditions: Melanoma

Interventions: Behavioral: Interview

First Posted Date: 2006-10-31

Last Posted Date: 2019-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 205

Registration Number: NCT00394134

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Cetuximab

First Posted Date: 2006-10-26

Last Posted Date: 2012-09-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00392769

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
🇺🇸
New York Presbyterian Hospital-Cornell Medical Center, New York, New York, United States

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Phase 2

Completed

Conditions: BCR-ABL1 Fusion Protein Expression
Recurrent Acute Lymphoblastic Leukemia
t(9;22)
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Methotrexate
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2006-10-20

Last Posted Date: 2025-02-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT00390793

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Radiation Therapy
Behavioral: Questionnaire
Drug: Bicalutamide
Drug: Leuprolide
Drug: Goserelin
Drug: Flutamide

First Posted Date: 2006-10-17

Last Posted Date: 2012-08-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00388804

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2006-10-16

Last Posted Date: 2014-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00388154

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The Woman's Hospital of Texas, Houston, Texas, United States
🇺🇸
St. Lukes Episcopal Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy